Navigation Links
Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
Date:7/30/2009

Findings May Potentially Lead to New Approach to Stroke Treatment

BOCA RATON, Fla., July 30 /PRNewswire-USNewswire/ -- When minimally invasive endovascular (through the vessel) therapy made its debut two decades ago, stroke care underwent a major shift as the "window of treatment" for patients suffering a stroke was expanded to eight hours within symptom onset, rather than the standard three-hour window required by the FDA-approved intravenous tPA therapy. Now, a new retrospective, multi-center study shows that endovascular therapy beyond the eight-hour window restored blood flow in the brain in approximately 74 percent of patients suffering ischemic (caused by a clot) stroke. Presented today at the Society of NeuroInterventional Surgery (SNIS) 6th Annual Meeting in Boca Raton, FL, the data suggests that this treatment is safe and potentially leads to improved outcomes for a select number of late-presenting patients, including those who awake with stroke symptoms.

According to lead author Raul Nogueira, M.D., Assistant in Neurology and Radiology at Massachusetts General Hospital -- Harvard Medical School, presentation beyond eight hours of symptom onset has traditionally been the single most important factor in excluding patients from stroke treatment. Thus, continued Nogueira, when brain imaging studies revealed that a significant number of late-presenting stroke patients showed evidence of salvageable brain tissue in the area of the stroke, it was an important avenue to pursue. This meant that endovascular therapy (performed by neurointerventional specialists who use drugs or mechanical devices inserted through a catheter or narrow tube that is threaded up through the vessels directly to the problem site to dispel the clot) could potentially be utilized successfully in these patients.

"As we considered the possibilities, it became an exciting proposition to pursue our hypothesis," said Nogueira. "Traditionally, these patients had been deemed untreatable. But if the therapeutic window could be expanded, these findings could make a significant impact on the future of stroke treatment."

The study included a consecutive case series of 237 patients whose first angiography (a diagnostic test that infuses the blood vessels with dye in order to clearly visualize the vessel structures) confirming a clot in the brain was performed later than eight hours from the last time the patient was seen well. All patients were identified from prospectively acquire databases at 10 high volume academic stroke centers across the United States.

Of the 237 study participants, 49 percent were males and 51 percent were females, with a mean (or average) age of 64 years and whose mean time from last seen well to t reatment was 15 hours. On the standard National Institute of Health Stroke Scale (NIHSS) -- a test that uses baseline data to determine severity of a stroke and projected outcome -- participants registered a mean score of 15 (any score over 10 is associated with a serious stroke). Various endovascular treatments were used, including: clot-dissolving drugs in 46 percent of the cases; the MERCI Retriever, a clot-removal device, in 62 percent of cases; and other mechanical instruments, including the recently FDA-approved Penumbra Device, in 36 percent of cases.

Beyond the immediate results that showed an overwhelming success in restoring blood flow, follow-up at 90 days in 198 patients indicate that 93 (47 percent) patients registered good outcomes (meaning patients could be functionally independent) and 123 (62 percent) patients reflected acceptable outcomes. Approximately nine percent suffered a symptomatic brain hemorrhage and the overall mortality rate was 22 percent. When analyzing what factors were most closely associated with favorable outcomes, successful restoration of blood flow, younger age, lower stroke severity (as indicated by the NIHSS), and male gender were identified.

According to Nogueira, the study serves as preliminary data for DAWN, a prospective randomized trial designed to assess the benefit of this approach as compared to standard medical therapy. "We look forward to exploring this preliminary data more in-depth in order to bring more clarity to the treatment of late-presenting stroke patients. The possibilities are exciting, as these findings could very well mean that thousands of patients who would not have been previous candidates for treatment could benefit from therapies that could restore their quality of life."

Stroke is the third leading cause of death in the United States, Canada, Europe and Japan. According to the American Stroke Association, approximately 800,000 Americans each year suffer a new or recurrent stroke. Americans will pay close to $68.9 billion in 2009 for stroke-related medical costs and disability.

About SNIS

SNIS members are neurointerventional practitioners with backgrounds in neuroradiology, neurosurgery and neurology that come together in the shared discipline of neurointerventional surgery. Our practitioners specialize in minimally invasive and endovascular procedures to treat stroke, aneurysms, carotid stenosis and spine fractures. Over the past two decades, our physicians have made numerous contributions to the neurosciences including: advancing stroke treatment through catheter based therapy; innovating endovascular coiling for aneurysms; pioneering interventional procedures to treat fractures in the spine; and initiating the first-ever stroke registry to track procedural success in the treatment of acute stroke. More information on SNIS and our members' treatment specialties may be found at www.snisonline.org.


'/>"/>
SOURCE Society of NeuroInterventional Surgery
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
2. Cyberonics Provides Update on Depression Post-Approval Study
3. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
4. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
5. UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPars Investigational Cancer Drug BSI-201
6. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
8. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
9. New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
10. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
11. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
Breaking Medicine News(10 mins):